MABp1 is a True Human™ monoclonal antibody that specifically targets Interleukin 1alpha (IL-1α), a key alarmin that is involved in the initiation of sterile inflammation. MABp1 differs from previous generations of therapeutic antibodies in that it was cloned from an Epstein-Barr, virus-immortalized, human B cell that was isolated from an individual with endogenous anti-IL-1α antibodies and did not undergo any in-vitro affinity maturation. Thus, this molecule demonstrates an excellent safety and tolerability profile in clinical settings.
The precursor to IL-1α is constitutively present in numerous cells of healthy individuals, such as: platelets, epithelial cells of mucosal membranes throughout the body, the entire endothelium of vasculature, and cells of organs such as liver, lung, and kidney. Following an ischaemic or injurious event, the IL-1α precursor is released and moves to the cell surface membrane. There, by activating adjacent cells bearing the IL-1 receptor, it initiates the first step in the sterile inflammation pathway, triggering a cascade of inflammatory mediators, chemokines, and other cytokines.
Thus, the specific blockade of IL-1α activity can lift the burden for a broad spectrum of inflammatory diseases in rheumatology, dermatology, and in cardiovascular diseases. Furthermore, targeting IL-1α has also provided proof of concept for diseases that were not considered to be inflammatory, such as Type 2 diabetes and heart failure.